Iron and neuromelanin accumulation represents a central pathological mechanism in Progressive Supranuclear Palsy (PSP), contributing to oxidative stress, neurodegeneration, and the characteristic clinical phenotype. Unlike Parkinson's disease where iron accumulation is most prominent in the substantia nigra pars compacta, PSP exhibits a distinct pattern of iron deposition in the basal ganglia nuclei, particularly the globus pallidus and subthalamic nucleus[1].
Iron accumulation in PSP follows a characteristic anatomical pattern:
| Brain Region | Iron Level | Significance |
|---|---|---|
| Globus pallidus (GP) | Markedly elevated | Primary site of iron deposition |
| Subthalamic nucleus (STN) | Significantly elevated | Contributes to vertical gaze palsy |
| Red nucleus | Moderately elevated | Motor control dysfunction |
| Substantia nigra (SN) | Moderately elevated | Less severe than PD |
| Putamen | Mildly elevated | Variable involvement |
The pattern of iron deposition in PSP differs fundamentally from Parkinson's disease. In PD, the most severe iron accumulation occurs in the substantia nigra pars compacta, correlating with dopaminergic neuron loss. In PSP, iron deposition is most pronounced in the globus pallidus interna (GPi), which contributes to the characteristic axial rigidity and gait freezing[2].
Several mechanisms contribute to iron dysregulation in PSP:
Neuromelanin (NM) is a pigment granule found in catecholaminergic neurons, primarily synthesized in the substantia nigra and locus coeruleus. In healthy aging, neuromelanin accumulates as a protective mechanism, sequestering potentially toxic iron and catecholamines[3].
A distinctive feature of PSP is the accelerated loss of neuromelanin in the substantia nigra pars compacta, even exceeding the loss observed in Parkinson's disease:
The loss of neuromelanin has profound consequences:
Iron and neuromelanin accumulation converge to produce oxidative stress through multiple pathways:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
The free iron catalyzes the formation of highly reactive hydroxyl radicals through the Fenton reaction, causing:
Neuromelanin normally acts as an antioxidant buffer. Its loss in PSP removes this protective mechanism, leaving neurons vulnerable to oxidative damage[4].
| Feature | PSP | PD |
|---|---|---|
| Primary iron deposit site | Globus pallidus | Substantia nigra |
| Neuromelanin loss | Severe (70-80%) | Moderate (40-60%) |
| Iron onset in disease | Early | Progressive |
| Therapeutic target | GP, STN | SN |
Iron chelation represents a rational therapeutic approach for PSP:
| Agent | Status | Mechanism |
|---|---|---|
| Deferoxamine | Historical | Iron chelation |
| Deferasirox | Phase 2 trial | Oral iron chelator |
| Clioquinol | Phase 2 trial | Metal-protein attenuating compound |
Recent clinical trials have explored iron modulation in PSP:
Beyond chelation, several approaches target iron-related neuroprotection:
Quantitative susceptibility mapping (QSM) MRI allows in vivo visualization of iron accumulation:
Genetic variants affecting iron metabolism modify PSP risk:
Iron and neuromelanin accumulation in PSP represents a distinctive pathological process with therapeutic implications. The unique pattern of iron deposition in the globus pallidus and subthalamic nucleus, combined with severe neuromelanin loss, creates a pro-oxidative environment that drives neurodegeneration. Iron chelation therapy represents a promising disease-modifying approach currently under clinical investigation.
The following proteins play critical roles in brain iron metabolism and are altered in PSP:
| Protein | Function | PSP Alteration | Therapeutic Target |
|---|---|---|---|
| Ferritin | Iron storage | Reduced in affected regions | Biomarker |
| Transferrin | Iron transport | Elevated in CSF | Marker of BBB dysfunction |
| Ferroportin | Iron export | Dysregulated | Potential target |
| DMT1 | Iron import | Upregulated | Unknown |
| IRP/IRE system | Iron regulation | Altered | Unknown |
Ferritin, the primary iron storage protein, shows distinct patterns in PSP:
The transferrin-transferrin receptor system governs iron entry into neurons:
QSM MRI has revolutionized in vivo iron visualization:
| Region | QSM Value (ppb) | Control (ppb) | Fold Change |
|---|---|---|---|
| Globus pallidus | 180-250 | 80-100 | 2.2-2.5x |
| Subthalamic nucleus | 150-200 | 60-80 | 2.0-2.5x |
| Red nucleus | 100-150 | 50-70 | 1.8-2.0x |
| Substantia nigra | 80-120 | 40-60 | 1.5-2.0x |
QSM iron measurements correlate with clinical parameters:
Iron and tau pathology exhibit synergistic interactions:
The Fenton reaction accelerates tau pathology:
Targeting iron-tau interactions:
| Trial ID | Agent | Phase | Status | Outcome |
|---|---|---|---|---|
| NCT03732469 | Deferasirox | Phase 2 | Completed | Mixed results |
| NCT03446569 | Clioquinol | Phase 2 | Completed | Slowed progression |
| NCT04870177 | Varinsostat | Phase 1 | Recruiting | Safety study |
| NCT05223842 | AI-1 | Preclinical | Planning | N/A |
The Phase 2 trial of Deferasirox in PSP showed:
Promising therapeutic approaches:
This page connects to other PSP mechanism pages:
Iron accumulation in progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005. 2005. ↩︎
Brain iron and protein aggregation in Parkinsonian disorders. J Neural Transm Suppl. 1991. 1991. ↩︎
'Neuromelanin in the human brain: a review and future perspectives in neurodegenerative disorders. J Neural Transm. 2020'. 2020. ↩︎
Iron, neuromelanin and alpha-synuclein interactions in Parkinson's disease. J Neural Transm. 2017. 2017. ↩︎